Trial | NCT00168922  Report issue

Title

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Phase II Study to Determine the Efficacy of Bendamustin (Ribomustin) in Patients With Recurrent Small Cell Bronchial Carcinoma After Cytostatic Polychemotherapy

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    bendamustine ...

  • Study Participants

    50
Determination of response rate Assessment of toxicity and determination of "time to progression"
Phase II Study to determine the efficacy of Bendamustin(Ribomustin) in patients with recurrent small cell bronchial carcinoma after cytostatic polychemotherapy
Study Started
Feb 28
2001
Study Completion
Dec 31
2006
Last Update
Apr 27
2006
Estimate

Drug Bendamustin/Ribomustin

Criteria 

Inclusion Criteria:

Patients with histological proven, curative non treatable small lung cell carcinoma
Recurrence >8 weeks, > 1 year after 1st line treatment with platin- and etoposide polychemotherapy, without brain metastases

Exclusion Criteria:

Brain metastases
WHO-PS 3 - 4
No Results Posted